Aspira Pathlab & Diagnostics Ltd Financials
Company Logo

Aspira Pathlab & Diagnostics Ltd Financial Statement

Aspira Pathlab & Diagnostics Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue4.73
Operating Expense4.29
Net Profit-0.02
Net Profit Margin-0.42
Earning Per Share-0.02
EBIDTA0.44
Effective Tax RateTBA

Aspira Pathlab & Diagnostics Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual13.20
Operating Expenses Annual14.39
Operating Profit Annual-0.77
Interest Annual0.37
Depreciation1.51
Net Profit Annual-2.67
Tax AnnualTBA

Aspira Pathlab & Diagnostics Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.57
Cash Flow from Operations1.05
Cash Flow from Investing0.14
Cash Flow from Financing-0.95
Cash Flow at the End0.80

Aspira Pathlab & Diagnostics Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-5.76
PBIT Margin (%)-17.42
PBT Margin (%)29.70
Net PROFIT Margin (%)-20.23
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-18.00
Total Debt / Equity (X)0.16
Asset Turnover Ratio (%)0.89

Aspira Pathlab & Diagnostics Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual6.79
Total Current Assets Annual4.36
Non Current Assets Annual10.35
Total Shareholders Funds Annual10.14
Total Assets Annual14.71

Aspira Pathlab & Diagnostics Ltd Earning Calls

EPS (INR)

Expected

0.05

Reported

0.05

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Jun 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Sep 20, 2024, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 31.91 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Aspira Pathlab & Diagnostics Ltd is debt-free with a debt-to-equity ratio of 0.27.
In FY 2023 , Aspira Pathlab & Diagnostics Ltd recorded a total revenue of approximately 13.20 Cr marking a significant milestone in the company's financial performance.
Aspira Pathlab & Diagnostics Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.4% and -0.2% annually, respectively..
Aspira Pathlab & Diagnostics Ltd's current PE ratio is -11.95.
Aspira Pathlab & Diagnostics Ltd's ROCE averaged 4.4% from the FY ending March 2022 to 2024, with a median of 2.0%. It peaked at 28.9% in March 2022, reflecting strong capital efficiency over the period..
Aspira Pathlab & Diagnostics Ltd's latest EBIT is Rs. -2.30 Cr, surpassing the average EBIT of Rs. 0.95 Cr over the 5 years..